HBcAb Positivity Is a Risk Factor for an Increased Detectability of HIV RNA after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Analysis of a Multicenter Italian Cohort.
2DR
3TC/DTG
HIV/HBV coinfection
anti-HBc
dual therapy
Journal
Microorganisms
ISSN: 2076-2607
Titre abrégé: Microorganisms
Pays: Switzerland
ID NLM: 101625893
Informations de publication
Date de publication:
15 Feb 2021
15 Feb 2021
Historique:
received:
15
01
2021
revised:
09
02
2021
accepted:
11
02
2021
entrez:
6
3
2021
pubmed:
7
3
2021
medline:
7
3
2021
Statut:
epublish
Résumé
The aim of this study was to evaluate whether the presence of anti-hepatitis B (HBV) c antibodies (HBcAb positivity) could influence the control of Human Immunodeficiency Virus (HIV) viremia in patients living with HIV (PLWH) who switch a to two-drug antiretroviral therapy (2DR) containing lamivudine (3TC) (2DR-3TC). A retrospective observational multicenter study was conducted on 166 PLWH switching to the 2DR-3TC-based regimen: 58 HBcAb-positive and 108 HBcAb-negative patients. The HBcAb-positive PLWH group demonstrated a significantly higher percentage of subjects with very low-level viremia at all time points after switching (6th month: <31% vs. 17.6%,
Identifiants
pubmed: 33671934
pii: microorganisms9020396
doi: 10.3390/microorganisms9020396
pmc: PMC7919011
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
AIDS. 2019 Nov 1;33(13):2005-2012
pubmed: 31306175
J Med Virol. 2007 Oct;79(10):1464-71
pubmed: 17705185
J Biol Chem. 2001 Sep 21;276(38):35435-43
pubmed: 11457829
Infection. 2009 Oct;37(5):445-9
pubmed: 19669092
World J Gastroenterol. 2014 Oct 28;20(40):14598-614
pubmed: 25356024
BMC Infect Dis. 2018 May 8;18(1):214
pubmed: 29739341
Eur J Gastroenterol Hepatol. 2019 Nov;31(11):1403-1407
pubmed: 30969194
Proc Natl Acad Sci U S A. 1989 Jul;86(13):5168-72
pubmed: 2740349
J Acquir Immune Defic Syndr. 2012 Aug 15;60(5):473-82
pubmed: 22481602
Open Forum Infect Dis. 2017 Sep 13;4(4):ofx195
pubmed: 29062862
Microorganisms. 2020 Nov 18;8(11):
pubmed: 33218205
J Clin Virol. 2014 Aug;60(4):347-53
pubmed: 24881491
J Antimicrob Chemother. 2010 Mar;65(3):379-82
pubmed: 20085999
Curr Opin Infect Dis. 2012 Feb;25(1):17-25
pubmed: 22156900
Viruses. 2020 Jun 11;12(6):
pubmed: 32545313
J Hepatol. 1998 Aug;29(2):306-9
pubmed: 9722213
BMC Infect Dis. 2011 Nov 04;11:310
pubmed: 22054111
Sci Rep. 2019 Aug 16;9(1):11942
pubmed: 31420570
J Clin Virol. 2018 Nov;108:50-52
pubmed: 30240941
Open Forum Infect Dis. 2018 Oct 05;5(10):ofy251
pubmed: 30377627
Clin Infect Dis. 2013 Nov;57(10):1489-96
pubmed: 23946221
J Infect Dis. 2004 Apr 1;189(7):1185-92
pubmed: 15031786
J Virol Methods. 2015 Jun 1;217:8-13
pubmed: 25724435
J Hepatol. 2019 Aug;71(2):397-408
pubmed: 31004683
J Infect Dis. 2013 Nov 1;208(9):1454-8
pubmed: 23901088
PLoS One. 2017 Jun 7;12(6):e0179035
pubmed: 28591184